Related Experiment Video
Updated: May 10, 2026
05:21
Laparoscopic Extracorporeal Knot-Tying for Uterine Vessel Occlusion during Hysterectomy with Cervical Cerclage in Large Uteri
Published on: September 12, 2025
Laparoscopic supracervical hysterectomy using EnSeal vs standard bipolar coagulation technique: randomized controlled
Ralf Rothmund1, Bernhard Kraemer, Sara Brucker
1Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.
Journal of Minimally Invasive Gynecology
|June 25, 2013
Summary
The EnSeal device reduced operative time during laparoscopic supracervical hysterectomy (LASH). This study found EnSeal to be as reliable as standard bipolar forceps for LASH procedures.
Area of Science:
- Minimally Invasive Gynecologic Surgery
- Surgical Technology Evaluation
Background:
- Laparoscopic supracervical hysterectomy (LASH) is a common gynecologic procedure.
- Effective hemostasis and operative efficiency are key considerations in LASH.
Purpose of the Study:
- To compare the efficacy and safety of the EnSeal device versus standard bipolar coagulation forceps in LASH.
- To evaluate operative time, blood loss, and postoperative outcomes.
Main Methods:
- Prospective, randomized, controlled trial involving 160 patients undergoing LASH.
- Patients were divided into two groups: EnSeal device (n=80) and standard bipolar forceps (n=80).
- Canadian Task Force classification I study conducted at a university hospital.
Main Results:
- Mean operative time was significantly shorter with the EnSeal device (78.18 min) compared to standard forceps (86.30 min) (p = .03).
- Significantly less blood loss (p < .001) and shorter hospital stay (p = .03) were observed in the EnSeal group.
- No significant differences in postoperative pain scores or complications were noted between groups.
Conclusions:
- The EnSeal device offers a shorter resection time in LASH compared to standard bipolar forceps.
- EnSeal demonstrated comparable safety and reliability to conventional electrocoagulation techniques.
- The findings support EnSeal as a viable alternative for achieving hemostasis during LASH.
